Fluvoxamine in the treatment of anxiety disorders

(2912) Views  (429) Full article downloads

Authors: Jane Irons

Published Date February 2005 Volume 2005:1(4) Pages 289 - 299

DOI: http://dx.doi.org/10.2147/NDT.S

Jane Irons

Dove Medical Press, Auckland, New Zealand

Abstract: Fluvoxamine is a selective-serotonin reuptake inhibitor (SSRI) that has proved effective in large double-blind, randomized, controlled trials involving patients with social anxiety disorder (SAD), obsessive-compulsive disorder (OCD), and panic disorder. Improvements have also been demonstrated in patients with post-traumatic stress disorder, as well as those with a range of obsessive-compulsive spectrum disorders including binge eating disorder, bulimia nervosa, pathological gambling, and body dysmorphic disorder. Several well controlled studies have confirmed the efficacy of fluvoxamine in children and adolescents with OCD, SAD, and other anxiety disorders, and it was the first SSRI to be registered for the treatment of OCD in children. Fluvoxamine is well tolerated. In common with other SSRIs, the most frequently reported adverse event is nausea. Fluvoxamine does not cause sedation or cognitive impairment and is associated with a low risk of sexual dysfunction, suicidality, and withdrawal reactions. It is safe in overdose and has no significant effect on body weight or cardiovascular parameters.

Keywords: fluvoxamine, anxiety disorders, obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder

Readers of this article also read: